Boston Scientific Corp
NYSE:BSX

Watchlist Manager
Boston Scientific Corp Logo
Boston Scientific Corp
NYSE:BSX
Watchlist
Price: 90 USD -1.64% Market Closed
Market Cap: 132.6B USD
Have any thoughts about
Boston Scientific Corp?
Write Note

Boston Scientific Corp
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Boston Scientific Corp
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Boston Scientific Corp
NYSE:BSX
Total Current Liabilities
$5.9B
CAGR 3-Years
14%
CAGR 5-Years
7%
CAGR 10-Years
12%
Becton Dickinson and Co
NYSE:BDX
Total Current Liabilities
$8.9B
CAGR 3-Years
11%
CAGR 5-Years
10%
CAGR 10-Years
15%
Edwards Lifesciences Corp
NYSE:EW
Total Current Liabilities
$1.9B
CAGR 3-Years
26%
CAGR 5-Years
20%
CAGR 10-Years
16%
Stryker Corp
NYSE:SYK
Total Current Liabilities
$7.7B
CAGR 3-Years
20%
CAGR 5-Years
14%
CAGR 10-Years
6%
Abbott Laboratories
NYSE:ABT
Total Current Liabilities
$13.8B
CAGR 3-Years
2%
CAGR 5-Years
6%
CAGR 10-Years
2%
Intuitive Surgical Inc
NASDAQ:ISRG
Total Current Liabilities
$1.7B
CAGR 3-Years
18%
CAGR 5-Years
12%
CAGR 10-Years
13%
No Stocks Found

Boston Scientific Corp
Glance View

Market Cap
132.6B USD
Industry
Health Care

Boston Scientific Corp., a global leader in medical devices, has carved out an impressive niche at the intersection of healthcare innovation and patient care. Founded in 1979, the company has since grown into a powerhouse with a diverse portfolio that includes products for cardiology, rhythm management, endoscopy, urology, and more. With a commitment to advancing science and improving lives, Boston Scientific is dedicated to developing cutting-edge technologies that address some of the most pressing challenges in medicine today. This commitment is paired with a strong focus on value creation, making the company's long-term strategy particularly appealing to investors looking for stable growth in the healthcare sector. As a publicly traded company on the New York Stock Exchange under the ticker symbol BSX, Boston Scientific has demonstrated resilience and adaptability, with consistent revenue growth driven by innovation and strategic acquisitions. The company's R&D investments are supported by a robust pipeline of new products and therapies, which promise to enhance therapeutic options and improve patient outcomes. For investors, Boston Scientific represents not just an opportunity to participate in a thriving industry with strong demand fundamentals, but also a chance to align with a firm that embodies the principles of prudent financial management and value creation akin to the teachings of Warren Buffett and Charlie Munger. With a proactive approach to market trends and a commitment to sustainability, Boston Scientific is well-positioned to navigate the evolving healthcare landscape, making it a compelling choice for investors seeking exposure to the lucrative medical devices arena.

BSX Intrinsic Value
62.59 USD
Overvaluation 30%
Intrinsic Value
Price

See Also

What is Boston Scientific Corp's Total Current Liabilities?
Total Current Liabilities
5.9B USD

Based on the financial report for Sep 30, 2024, Boston Scientific Corp's Total Current Liabilities amounts to 5.9B USD.

What is Boston Scientific Corp's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
12%

Over the last year, the Total Current Liabilities growth was 29%. The average annual Total Current Liabilities growth rates for Boston Scientific Corp have been 14% over the past three years , 7% over the past five years , and 12% over the past ten years .

Back to Top